Cargando…

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients

Belatacept is an intravenously infused selective T cell costimulation blocker approved for preventing organ rejection in renal transplant recipients aged ≥18 years. This phase I trial examined the pharmacokinetics and pharmacodynamics (percentage CD86 receptor occupancy [%CD86RO]) of a single dose o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moudgil, Asha, Dharnidharka, Vikas R., Feig, Daniel I., Warshaw, Barry L., Perera, Vidya, Murthy, Bindu, Roberts, Mustimbo E., Polinsky, Martin S., Ettenger, Robert B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590112/ https://www.ncbi.nlm.nih.gov/pubmed/30582294 http://dx.doi.org/10.1111/ajt.15236

Ejemplares similares

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study
por: Bremer, Sara, et al.
Publicado: (2009)

Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
por: Vincenti, F., et al.
Publicado: (2017)

De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT studies
por: Bray, R. A., et al.
Publicado: (2018)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept
por: Chavarot, Nathalie, et al.
Publicado: (2021)

Posttransplant reduction in preexisting donor‐specific antibody levels after belatacept‐ versus cyclosporine‐based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT‐EXT
por: Bray, R. A., et al.
Publicado: (2018)

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
por: Merali, Samira J., et al.
Publicado: (2023)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Low-Dose Antithymocyte Globulin Has No Disadvantages to Standard Higher Dose in Pediatric Kidney Transplant Recipients: Report From the Pediatric Nephrology Research Consortium
por: Ashoor, Isa F., et al.
Publicado: (2021)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza
por: Bautista, Francisco, et al.
Publicado: (2019)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Hypertension in the Pediatric Kidney Transplant Recipient
por: Charnaya, Olga, et al.
Publicado: (2017)

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
por: Perera, Vidya, et al.
Publicado: (2022)

Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study
por: Durrbach, A., et al.
Publicado: (2016)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
por: Perera, Vidya, et al.
Publicado: (2022)

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
por: Coscia, Lisa, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019
por: McEneny-King, Alanna C., et al.
Publicado: (2021)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
por: Wu, Yue-E, et al.
Publicado: (2022)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients
por: Cossart, Amelia R., et al.
Publicado: (2021)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
por: Gupta, Shruti, et al.
Publicado: (2018)

Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature
por: Deliège, Pierre-Guillaume, et al.
Publicado: (2020)

Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
por: Luque, Sonia, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013)

Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk—A Single Center Experience
por: Neuwirt, Hannes, et al.
Publicado: (2019)

2702. A Case Series of Kidney Transplant Recipients on Belatacept with CMV Infection in a Single Academic Center
por: Feller, Fionna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u579rsp3fdiq6j7lqkq8t9uuqr